Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.
Cadilha BL, Benmebarek MR, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S. Cadilha BL, et al. Among authors: feuchtinger t. Sci Adv. 2021 Jun 9;7(24):eabi5781. doi: 10.1126/sciadv.abi5781. Print 2021 Jun. Sci Adv. 2021. PMID: 34108220 Free PMC article.
The role of haematopoietic stem cell transplantation for sickle cell disease in the era of targeted disease-modifying therapies and gene editing.
de la Fuente J, Gluckman E, Makani J, Telfer P, Faulkner L, Corbacioglu S; Paediatric Diseases Working Party of the European Society for Blood and Marrow Transplantation. de la Fuente J, et al. Lancet Haematol. 2020 Dec;7(12):e902-e911. doi: 10.1016/S2352-3026(20)30283-0. Lancet Haematol. 2020. PMID: 33242447 Review.
Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins.
Blaeschke F, Stenger D, Apfelbeck A, Cadilha BL, Benmebarek MR, Mahdawi J, Ortner E, Lepenies M, Habjan N, Rataj F, Willier S, Kaeuferle T, Majzner RG, Busch DH, Kobold S, Feuchtinger T. Blaeschke F, et al. Among authors: feuchtinger t. Blood Cancer J. 2021 Jun 4;11(6):108. doi: 10.1038/s41408-021-00499-z. Blood Cancer J. 2021. PMID: 34088894 Free PMC article. No abstract available.
Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy.
Lorenzini T, Cadilha BL, Obeck H, Benmebarek MR, Märkl F, Michaelides S, Strzalkowski T, Briukhovetska D, Müller PJ, Nandi S, Winter P, Majed L, Grünmeier R, Seifert M, Rausch S, Feuchtinger T, Endres S, Kobold S. Lorenzini T, et al. Among authors: feuchtinger t. Br J Cancer. 2023 Sep;129(4):696-705. doi: 10.1038/s41416-023-02332-9. Epub 2023 Jul 4. Br J Cancer. 2023. PMID: 37400680 Free PMC article.
Approaches for bridging therapy prior to chimeric antigen receptor T cells for relapsed/refractory acute lymphoblastic B-lineage leukaemia in children and young adults.
Feuchtinger T, Bader P, Subklewe M, Breidenbach M, Willier S, Metzler M, Gökbuget N, Hauer J, Müller F, Schlegel PG, Frühwald M, Schmid C, Troeger A, Baldus C, Meisel R, Künkele A, Topp M, Bourquin JP, Cario G, Von Stackelberg A, Peters C. Feuchtinger T, et al. Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.283780. Online ahead of print. Haematologica. 2024. PMID: 38356450 Free article.
Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia.
Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring M, Feucht J, Feuchtinger T. Blaeschke F, et al. Among authors: feuchtinger t. Cancer Immunol Immunother. 2018 Jul;67(7):1053-1066. doi: 10.1007/s00262-018-2155-7. Epub 2018 Mar 31. Cancer Immunol Immunother. 2018. PMID: 29605883 Free PMC article.
Results of CoALL 07-03 study childhood ALL based on combined risk assessment by in vivo and in vitro pharmacosensitivity.
Schramm F, Zur Stadt U, Zimmermann M, Jorch N, Pekrun A, Borkhardt A, Imschweiler T, Christiansen H, Faber J, Schmid I, Feuchtinger T, Beron G, den Boer ML, Pieters R, Horstmann MA, Janka-Schaub GE, Escherich G. Schramm F, et al. Among authors: feuchtinger t. Blood Adv. 2019 Nov 26;3(22):3688-3699. doi: 10.1182/bloodadvances.2019000576. Blood Adv. 2019. PMID: 31765480 Free PMC article.
138 results